Skip to main content

Day: September 27, 2021

ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis

Approved for use in Japan in patients with microscopic polyangiitis and granulomatosis with polyangiitis SAN CARLOS, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) to market TAVNEOS™ (avacopan), an orally administered selective complement 5a receptor inhibitor, in Japan for the treatment of patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two main forms of anti-neutrophil cytoplasmic autoantibody-associated vasculitis also known as ANCA-associated vasculitis or ANCA vasculitis. ChemoCentryx’s Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan in markets...

Continue reading

Nanox to Announce Zebra Medical Vision Secures 8th 510K FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of its Population Health Offering

NEVE ILAN, Israel, Sept. 27, 2021 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Zebra Medical Vision secures 8th 510K FDA clearance for its Coronary Artery Calcium (CAC) solution as part of its population health offering. On August 10th, 2021 Nanox announced that it had entered into an acquisition agreement via merger with Zebra Medical Vision LTD. This agreement, once consummated, will put Zebra-Med on track to expand its mission of helping to diagnose populations at scale with its AI-based solutions, enabling IDNs and commercial payers to detect and treat patients at risk for chronic conditions while accurately adjusting their covered population risk. About Nanox:Nanox, founded by the serial entrepreneur...

Continue reading

Ehave Announces Inclusion in the 2021 Psychedelic Investor Guide

MIAMI, Sept. 27, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today that it has been included in the 2021 Psychedelic Investor Guide. The Psychedelic Investor Guide covers biotechnology, pharmaceutical and life sciences companies that are leading the emerging psychedelics medicine industry. Ben Kaplan, Ehave President and CEO stated, “Ehave’s inclusion in the Psychedelic Investor Guide is further validation of our strategy of integrating digital therapeutics with psychedelic medicine to improve mental health and increase productivity. Ehave is proud to be recognized as one of the leaders in this emerging space and our inclusion in the Guide will increase investor awareness to the Company’s progress, as we launch...

Continue reading

Iceland Seafood International hf: Completion of the acquisition of Ahumados Dominguez

Further to announcements on September 16th and 17th Iceland Seafood is pleased to confirm that the acquisition of 85% share in Ahumados Dominguez has now been closed. All terms remain as previously announced.   Share issuance in relation to the acquisition will now been processed in accordance with announcement on September 20th.  

Continue reading

Chorus Aviation announces closing of $85 million bought deal offering of 5.75% Senior Unsecured Debentures

NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES HALIFAX, Nova Scotia, Sept. 27, 2021 (GLOBE NEWSWIRE) — Chorus Aviation Inc. (“Chorus” or the “Company”) (TSX: CHR) announced today that it has completed its previously announced bought deal public offering of $85 million aggregate principal amount of senior unsecured debentures (the “Debentures”) at a price of $1,000 per Debenture (the “Offering”). The net proceeds of the Offering will be used primarily to partially redeem existing indebtedness, including the Company’s 6.00% senior debentures due December 31, 2024 (the “6.00% Debentures”) and, in certain circumstances, the US$100 million revolving facility, as well as for working capital and general corporate purposes. The 6.00% Debentures are currently secured by certain Dash 8-100 and Dash 8-300 aircraft,...

Continue reading

Jyske Realkredit to open 2% bond with 10-year interest only option and maturity in 2053

To Nasdaq Copenhagen A/S                                27 September 2021                                        Announcement no. 92/2021 Jyske Realkredit to open 2% bond with 10-year interest only option and maturity in 2053 Jyske Realkredit will issue new covered bonds (særligt dækkede obligationer) from Capital Centre E. The bonds will be DKK-denominated fixed-rate callable bonds with a 2% coupon rate, 10-year interest only option and maturity on 1 October 2053. The bonds will be registered with VP SECURITIES A/S and Jyske Realkredit will apply for admission to trading of the bonds on NASDAQ Copenhagen A/S. The final terms will be published in a separate stock exchange announcement. Yours sincerelyJyske Realkredit www.jyskerealkredit.com

Continue reading

High Grade Gold Intersected in First Drill Program at Talga Talga Gold Project

Figure 1Map showing conglomerate and basement prospects across the Pilbara.Figure 2Recent RC drilling program at the Talga Gold Project.Figure 3Two type cross sections showing best intersections at NW Australian. Sections are spaced 80m apart.Figure 4Recently completed detailed geology map, showing fault complexity around two key sections (Figure 3).Figure 5Cross section showing the second shear intersected at McPhees Reward.HIGHLIGHTSReverse Circulation (“RC”) drilling program intersects high-grade mineralization at Novo’s Talga Talga Gold Project (“Talga Gold Project”) in the Pilbara region of Western Australia Results include 3 m at 25.5 g/t Au from 28 m, and 3 m at 23.3 g/t Au from 11 m at the NW Australian prospect These are significant drilling...

Continue reading

Erasca is Named One of Fierce Biotech’s “Fierce 15” Biotechnology Companies of 2021

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Fierce Biotech has named it as one of 2021’s “Fierce 15” biotechnology companies, identifying Erasca as one of the industry’s most promising biotechnology companies. “Speaking with this year’s class of Fierce 15 winners showed us that not even a global pandemic can stop incredible innovations in medicine, and we’re on the cusp of some new breakthrough treatments despite unprecedented disruption last year,” said Annalee Armstrong, Senior Editor of Fierce Biotech. “The Fierce Biotech team heard one thing in common from our 2021 Fierce 15 winners: strong teams of scientists...

Continue reading

Authority to Operate on AWS Brings Splunk, Telos Corporation and stackArmor Together to Create a Simple and Fast Way to Help Achieve Compliance

FASTTR initiative enhances stackArmor’s ThreatAlert by building on market-leading Telos’ Xacta for security compliance documentation and Splunk for security information and event managementSplunk, Telos Corporation and stackArmor to Simplify and Accelerate ATO on AWSFASTTR initiative enhances stackArmor’s ThreatAlert by building on market-leading Telos’ Xacta for security compliance documentation and Splunk for security information and event managementASHBURN, Va. and TYSONS CORNER, Va., Sept. 27, 2021 (GLOBE NEWSWIRE) — Telos® Corporation (NASDAQ: TLS), Splunk Inc (NASDAQ: SPLK) and stackArmor are excited to announce their partnership under the authority to operate (ATO) on Amazon Web Services (AWS) program to reduce the time and cost associated with ATO compliance through the new FASTTR initiative, which stands...

Continue reading

Nabis Holdings Inc. Announces Postponement of Noteholders’ Meeting

VANCOUVER, British Columbia, Sept. 27, 2021 (GLOBE NEWSWIRE) — Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: A2PL) (the “Company”) today announced that it is postponing the meeting of the registered holders of the $23,000,000 principal amount of 5.3% promissory notes due January 25, 2023 (the “Notes”) previously scheduled for September 27, 2021 (the “Noteholders’ Meeting”) to such other date to be determined and announced by the Company. The postponement is permitted by the interim order concerning the holding of the Noteholders’ Meeting granted by the Supreme Court of British Columbia as previously announced on September 15, 2021. The record date for determining the Noteholders eligible to vote at the Noteholders’ Meeting remains August 24, 2021. Noteholders who have already submitted a proxy may not need to vote again for...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.